The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NTLA | +61.51% | +2.89% | +0.57% | +16% |
| S&P | +16.9% | +95.99% | +14.39% | +230% |
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Some math suggests that even Wall Street is lowballing the stock's potential.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $14.25M | 104.8% |
| Gross Profit | $11.75M | 169.5% |
| Gross Margin | 82.45% | 19.8% |
| Market Cap | $971.61M | -55.0% |
| Market Cap / Employee | $2.41M | 0.0% |
| Employees | 403 | -23.4% |
| Net Income | -$101.26M | 31.1% |
| EBITDA | -$107.50M | 21.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $156.35M | 19.5% |
| Accounts Receivable | $11.35M | -7.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $75.60M | -13.4% |
| Short Term Debt | $26.99M | 42.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -45.94% | -5.5% |
| Return On Invested Capital | -34.83% | -2.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$99.86M | -68.7% |
| Operating Free Cash Flow | -$99.62M | -71.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.17 | 1.23 | 0.83 | 1.25 | -40.15% |
| Price to Sales | 48.17 | 20.52 | 16.15 | 18.41 | -61.01% |
| Price to Tangible Book Value | 2.17 | 1.23 | 0.83 | 1.25 | -40.15% |
| Enterprise Value to EBITDA | -10.69 | -5.95 | -3.14 | -5.73 | -50.70% |
| Return on Equity | -52.2% | -54.0% | -57.9% | -57.0% | 16.19% |
| Total Debt | $101.62M | $210.20M | $119.25M | $102.59M | -3.48% |
NTLA earnings call for the period ending October 3, 2021.
NTLA earnings call for the period ending June 30, 2021.
NTLA earnings call for the period ending March 31, 2021.
NTLA earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
